EP3692983B1 |
11 Aug, 2021
|
Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof
|
May, 2029
|
6
| |
EP3782611B1 |
06 Jul, 2022
|
Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof
|
May, 2029
|
5
| |
EP2223688B1 |
29 May, 2019
|
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
|
Mar, 2023
|
5
| |
EP3042659B8 |
19 Dec, 2018
|
Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
|
Sep, 2024
|
5
| |
EP3880802B1 |
07 Sep, 2022
|
Improved T Cell Manufacturing Process
|
Nov, 2039
|
1
| |
EP2687213B1 |
17 Jul, 2019
|
Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses Thereof
|
Mar, 2028
|
1
| |
EP3045175B8 |
19 Dec, 2018
|
Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
|
Sep, 2024
|
1
| |
EP3045176B8 |
12 Dec, 2018
|
Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
|
Sep, 2024
|
1
| |
EP2223687B1 |
17 May, 2017
|
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
|
Mar, 2023
|
1
| |